Menu
Situs Panduan dan Solusi Terkini

An exclusive AstraZeneca COVID-19 vaccine has been shipped to Canada and Mexico prior to appropriate factory inspections

  • Share
banner 468x60

banner 336x280

By Alison Martell, Carl O’Donnell and Cassandra Garrison



Close-up of the bottle: File photo: AstraZeneca's COVID-19 vaccine boxes are seen at a vaccination center in Algiers.


© Reuters/Ramzi Budina
FILE PHOTO: AstraZeneca’s COVID-19 vaccine boxes appear at a vaccination center in Algiers.

(Reuters) – Canada and Mexico imported millions of doses of the COVID-19 vaccine from AstraZeneca and offered them to the public without health officials properly examining the U.S. manufacturer’s operations, according to inspection records and pertinent regulators.



Group of people looking at cell phone: File photo: The coronavirus (COVID-19) vaccination in Monterrey


©Reuters/Daniel Bisrel
File: Coronavirus disease (COVID-19) vaccination in Monterrey

Emergent BioSolutions Inc’s Baltimore plant was producing vaccines for AstraZeneca Plc and Johnson & Johnson under a $628 million US government contract.

In late March, under pressure to aid other countries access COVID-19 vaccines, the Biden administration released 1.5 million doses of AstraZeneca to Canada, and 2.5 million doses to Mexico.

European regulators have stated that the Emergent plant is complying with “pleasing manufacturing practices,” and on that basis both Canada and Mexico have started using the vaccine, regulators in both countries told Reuters.

But the European Medicines Agency (EMA) told Reuters the certification was based on a secluded examination that focused on a part of the facility that was not actually producing AstraZeneca shots – a fact that had not previously been reported.

The U.S. Food and Drug Administration halted production at the plant three weeks later, following the J&J vaccine was found to be contaminated with substances used in AstraZeneca shots.

Food and Drug Administration inspectors later documented the unsanitary conditions and poorly trained staff at the plant, which was quickly reformed to make vaccines during the pandemic. Production remains stalled, with tens of millions of doses of both vaccines at a regulatory stalemate.

No reports of the disease have been linked to vaccines made by Emergent, and regulators have not claimed that the contaminated vaccines were given to anyone. Emergent said there was no evidence of contamination in AstraZeneca shots that were produced at its site.

But the details of the flawed approval process show weaknesses that can develop when national regulators share responsibility for overseeing the complicated global pharmaceutical industry. Those problems have been exacerbated by the urgency of the epidemic.

“It’s a risk, because who knows what standards are applied?” said Joel Lakeshin, Canadian professor and expert on drug regulation. He said Health Canada usually relies heavily on foreign regulators. “It’s a gap that exists outside of times of crisis.”

Emergent said in a statement that it “worked with health officials around the world to ensure that any vaccine material we make meets stringent safety and quality requirements prior it is released.”

AstraZeneca said vaccines made by Emergent have undergone more than 40 tests to meet safety, purity and quality requirements, and that its manufacturing standards are “rigorously evaluated and independently verified by regulators.”

Video: Cancer Report (The Standalone)

next one

next one

Health Canada told Reuters it was confident the vaccines it had received were safe, citing in part AstraZeneca’s quality control systems. Mexico’s health organization COFEPRIS said it remained “confident that the approval process was carried out with all necessary precision”.

Canada signed deals to formally recognize the certifications of some other regulators as beforetime as 2003, and the US and Europe reached similar deals in 2019.

European inspection

Early in the vaccine rollout, the European Union was due to receive doses of Emergent’s J&J vaccine. In beforetime February, Italian officials conducted a secluded inspection of the plant that focused only on areas where J&J was being produced “and not the AstraZeneca vaccine, which was not manufactured in Emergent for the EU market,” according to an EMA statement.

Health Canada said it is assuming that both products will be manufactured to the alike standard. “The quality regulations evaluated by EMA for this product will be applicable to all similar products made at this location,” it said in a statement.

That’s the mistaken approach, according to University of Ottawa professor Amir Al-Atran, who studies drug policy, including Health Canada’s reliance on foreign regulators.

“Precisely because they (products) were similar, cross-contamination is a risk,” he said. He said Canada was “out of the average” in approving AstraZeneca doses from the facility prior the Food and Drug Administration.

Health Canada said it has reviewed test results and quality control steps for every batch of vaccine sent to Canada.

Mexico’s COFEPRIS initially told Reuters that the Food and Drug Administration was responsible for certifying the US operations, but later confirmed that the plant had been certified by European regulators.

When Reuters shared the European regulators’ statement that they had not specifically evaluated AstraZeneca’s production, COFEPRIS said it would review the file, but remained confident in the approval process.

The Mexican regulator said the vaccines went through Emergent’s quality control systems, and two more times during the vial filling process that were handled by another manufacturer.

“When evaluating vaccines, the product and its entire production process are considered and examined,” she said in a statement.

Emergent’s contract with the US government is the focus of a congressional investigation, which has unearthed documents highlighting beforetime concerns about the Baltimore plant.

Shortly following the Trump administration announced Emergent’s contract final summer, vaccine officials visited the plant and wrote a report citing insufficient staffing and training. The report warned of the need to strengthen quality control, a process that requires “significant resources and commitment”.

The Food and Drug Administration, following a visit to the plant in February 2021, indicated in a June memo that Emergent’s employee turnover was lofty and that record keeping was insufficient. While European regulators said they were aware of the visit, Health Canada said it did not learn about it until final month.

A spokesperson for the US Food and Drug Administration said the agency is working closely with international partners, and that it notified various health authorities of its findings following its April 2021 inspection of the start-up facility.

Emergent said it is still working with the U.S. Food and Drug Administration to release more COVID-19 vaccine kits already in production.

“We have made tens of millions of doses that can be used to aid vaccinate people around the world as the epidemic shows no signs of slowing,” the company said.

(Reporting by Alison Martell in Toronto, Emilio Parodi in Milan, Francesco Guaracchio in Brussels, Karl O’Donnell in New York, Cassandra Garrison in Mexico City; Editing by Michelle Gershberg and Bill Bercrot)

Referensi: www.msn.com

banner 336x280
banner 120x600
  • Share